Nephrologist Reveals: Ozempic + SGLT2 = Ultimate Kidney Protection
In this video:
Dr. Sean Hashmi, MD, MS, FASN—board-certified Nephrologist and Obesity Medicine Specialist—reveals shocking FLOW trial results and why post-transplant weight gain destroys kidneys.
You'll discover exactly why combining GLP-1s with SGLT2 inhibitors may be the new gold standard for diabetic kidney disease protection.
Thanks for watching!
➤ KEY INSIGHTS YOU'LL DISCOVER:
FLOW trial: GLP-1s reduce kidney disease progression by 24% in diabetics
Post-transplant weight gain (BMI 35+) causes 4.5x faster kidney function decline
Why 1/3 of transplant patients gain 10%+ body weight within one year
➤ WATCH NEXT: Beyond Muscles: Creatine's Powerful Effects on Brain Health→ [ • Beyond Muscles: Creatine's Powerful Effect... ]
Have a question about this video? Drop it in the comments—I read every one and try to respond to as many as I can, often creating videos based on your questions!
CHAPTERS:
00:00 Welcome & Audio Update
01:40 FLOW Trial: GLP-1s for Kidney Protection
05:40 SGLT2 + GLP-1 Combination Therapy
08:45 Q&A: Pirfenidone, Blood Pressure
11:20 Post-Transplant Weight Gain Study
16:20 Q&A: Forxiga, Prednisone Alternatives
18:00 Creatine Nitrate + Caffeine Study
24:00 Q&A: CRP, Sleep, Black Eye Stories
SCIENTIFIC REFERENCES:
FLOW Trial published in Nature Medicine - semaglutide for diabetic kidney disease
NYU Transplant Center study on post-transplant weight gain (1,500 patients)
Jacksonville State University creatine nitrate + caffeine cognitive study
Multiple studies on SGLT2 inhibitor and GLP-1 combination therapy
CONNECT WITH DR. HASHMI:
Website: https://www.selfprinciple.org
Instagram: / seanhashmimd
Facebook: / seanhashmimd
TikTok: / seanhashmimd
Help someone you care about: If you know someone who could benefit from this information, please share this video—it might make a real difference in their health journey.
MEDICAL DISCLAIMER:
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider for medical decisions. Views expressed are Dr. Hashmi's alone and do not represent any employer or institution. Individual results may vary. Viewing does not establish a doctor-patient relationship.
#KidneyTransplant #FLOWTrial #GLP1 #seanhashmimd #SGLT2Inhibitors